FORA Capital LLC Makes New Investment in Zoetis Inc. $ZTS

FORA Capital LLC purchased a new stake in shares of Zoetis Inc. (NYSE:ZTS) in the first quarter, Holdings Channel.com reports. The institutional investor purchased 8,490 shares of the company’s stock, valued at approximately $1,398,000.

A number of other institutional investors have also made changes to their positions in ZTS. Vanguard Group Inc. boosted its stake in Zoetis by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company’s stock valued at $6,842,222,000 after purchasing an additional 189,287 shares during the period. Polen Capital Management LLC lifted its holdings in shares of Zoetis by 17.6% during the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock worth $1,448,401,000 after buying an additional 1,313,653 shares during the last quarter. Northern Trust Corp boosted its position in shares of Zoetis by 1.2% in the first quarter. Northern Trust Corp now owns 6,504,902 shares of the company’s stock valued at $1,071,032,000 after acquiring an additional 78,508 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of Zoetis by 2.2% in the first quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company’s stock worth $847,293,000 after acquiring an additional 109,791 shares during the last quarter. Finally, Unisphere Establishment increased its position in Zoetis by 7.3% during the fourth quarter. Unisphere Establishment now owns 4,800,000 shares of the company’s stock worth $782,064,000 after acquiring an additional 325,000 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

ZTS has been the subject of a number of research reports. Leerink Partnrs downgraded shares of Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Piper Sandler upped their price objective on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. UBS Group decreased their target price on Zoetis from $189.00 to $170.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 7th. Leerink Partners lowered Zoetis from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Finally, Stifel Nicolaus downgraded Zoetis from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $202.43.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of the company’s stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total value of $110,840.00. Following the sale, the executive vice president directly owned 15,129 shares in the company, valued at $2,571,930. This represents a 4.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

Zoetis Price Performance

Shares of Zoetis stock opened at $155.12 on Wednesday. The firm has a market cap of $68.75 billion, a P/E ratio of 26.70, a price-to-earnings-growth ratio of 2.49 and a beta of 0.88. The firm’s 50-day simple moving average is $153.53 and its 200-day simple moving average is $158.28. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. The firm had revenue of $2.46 billion during the quarter, compared to analysts’ expectations of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter last year, the company earned $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, research analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.